SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of March, 2006
SkyePharma PLC
SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.
Form 20-F X Form 40-F
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes No X
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _______
For Immediate Release 27 March, 2006
SkyePharma PLC
SkyePharma to Announce 2005 Full Year Results on 19 April
and to Hold Business Review Meeting on 21 June
LONDON, UK, 27 March 2006 - SkyePharma PLC (LSE: SKP, NASDAQ: SKYE) announces today that the Company will issue its financial results
for the year ended 31 December 2005 to the London Stock Exchange at 07:00 a.m. (BST) on Wednesday 19 April 2006. Later that morning
the Company will host an analyst presentation, which will be webcast live, to be followed by a US conference call.
Frank Condella, SkyePharma's Chief Executive Officer, will host the analyst presentation and the conference call. Investors and other
interested parties may view the live webcast at 10:00 a.m. (BST) on the Company's website at www.skyepharma.com under the Investor
Relations tab.
US investors and other interested parties may access the conference call at 10:00 a.m. EDT (15:00 BST) by dialling 1-800-762-6067 for
US participants and +1-480- 629-9566 for international participants. The slides of the presentation will be available on the
Company's website at www.skyepharma.com under the Investor Relations tab.
For those unable to listen to the live broadcast, a replay will be available shortly after the conference call by dialling
1-800-475-6701 for US participants and +1-320-365-3844 for international participants and entering Access Code 824129.
A Business Review meeting will be held on Wednesday 21 June 2006 at the offices of Buchanan Communications, 45 Moorfields, London and
will start at 09:30 a.m. Attendance is by invitation only but the meeting will be webcast. Further details of the agenda for this
meeting will be published nearer the day. This meeting will provide an opportunity to gain an in-depth awareness and understanding of
key products in our portfolio and pipeline and to meet members of our senior management team.
For further information please contact:
SkyePharma PLC +44 207 491 1777
Frank Condella, Chief Executive Officer
Peter Laing, Director of Corporate Communications +44 207 491 5124
Sandra Haughton, US Investor Relations +1 212 753 5780
Buchanan Communications +44 207 466 5000
Tim Anderson / Mark Court / Rebecca Skye Dietrich
Notes for editors:
About SkyePharma
SkyePharma PLC develops pharmaceutical products benefiting from world-leading drug delivery technologies that provide easier-to-use
and more effective drug formulations. There are now eleven approved and marketed products incorporating SkyePharma's technologies in
the areas of oral, injectable, inhaled and topical delivery, supported by advanced solubilisation capabilities. For more information,
visit www.skyepharma.com.
Certain statements in this news release are forward-looking statements and are made in reliance on the safe harbour provisions of the
U.S. Private Securities Litigation Act of 1995. Although SkyePharma believes that the expectations reflected in these forward-looking
statements are reasonable, it can give no assurance that these expectations will materialize. Because the expectations are subject to
risks and uncertainties, actual results may vary significantly from those expressed or implied by the forward-looking statements
based upon a number of factors, which are described in SkyePharma's 20-F and other documents on file with the SEC. Factors that could
cause differences between actual results and those implied by the forward-looking statements contained in this news release include,
without limitation, risks related to the development of new products, risks related to obtaining and maintaining regulatory approval
for existing, new or expanded indications of existing and new products, risks related to SkyePharma's ability to manufacture products
on a large scale or at all, risks related to SkyePharma's and its marketing partners' ability to market products on a large scale to
maintain or expand market share in the face of changes in customer requirements, competition and technological change, risks related
to regulatory compliance, the risk of product liability claims, risks related to the ownership and use of intellectual property, and
risks related to SkyePharma's ability to manage growth. SkyePharma undertakes no obligation to revise or update any such
forward-looking statement to reflect events or circumstances after the date of this release.
END
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
SkyePharma PLC
By: /s/ Douglas Parkhill
Name: Douglas Parkhill
Title:
Company Secretary
Date: March 27, 2006